LYMPHATIC CANCER PLAGUE
http://www.notmilk.com/lymph.html
An epidemic rise in one under-publicized category of cancers should
sound an alarm for all Americans. There is a powerful link to the
dramatic surge in lymphatic cancer: the 1994 approval of the genetically
engineered bovine growth hormone (rbGH). Before 1995, lymphatic cancers
were comparatively rare.
Today, if one adds up the total number of cancer deaths from breast,
prostate, lung, pancreatic, and genital cancers, they do not
cumulatively equal the number of deaths from lymphatic cancers. Do I
have your attention?
This year Americans will consume nearly 180 billion pounds of milk and
dairy products in various forms. That will average out to 666 pounds
per American, nearly 40% of the average American diet. Cheese eaters,
ice cream slurpers, and milk drinkers of both sexes and every age group
will be ingesting dairy products from hormonally-treated cows.
Most Americans are unaware that laboratory animals treated with
rbGH experienced enormous changes in their lymphatic systems. The
spleens of these animals grew dramatically.
The controversial genetically modified cow hormone was approved for
human consumption in February of 1994. Cancer statistics
have recently been published by the U.S. Census Bureau comparing death
rates from cancer by sex and age groups in 1980, 1990, and 1995. These
data support evidence of a runaway plague. All of America became a
laboratory study for rbGH, which is now in America's ice cream, cheese,
and pizza.
There are small increases and decreases in lymphatic cancer rates from
1980 to 1990 depending upon sex and age group. What happened in 1995
represents the most dramatic short-term increase of any single cancer in
the history of epidemiological discovery and analyses.
| DEATH RATES FROM LYMPHATIC CANCER BY SEX AND AGE (1980 - 1995) |
|||||||||
| (Deaths per 100,000 population in specified age group) | |||||||||
| AGE GROUPS |
MALE |
FEMALE | |||||||
| 1980 | 1990 | 1995 | increase | 1980 | 1990 | 1995 | increase | ||
| 35-44 | 4.3 | 4.5 | 36.5 | 811% | 2.4 | 2.1 | 44.0 | 2095% | |
| 45-54 | 10.2 | 10.9 | 143.7 | 1318% | 6.6 | 6.0 | 140.7 | 2345% | |
| 55-64 | 24.4 | 27.2 | 480.5 | 1767% | 16.8 | 16.7 | 357.5 | 2141% | |
| 65-74 | 48.1 | 56.8 | 1089.9 | 1919% | 34.4 | 39.5 | 690.7 | 1749% | |
| 75-84 | 80.0 | 104.5 | 1842.3 | 1763% | 57.6 | 71.2 | 1061.5 | 1495% | |
| 85+ | 93.2 | 140.5 | 2837.3 | 2019% | 63.0 | 90.0 | 1249.1 | 1588% | |
The approval process for rbGH was the most controversial drug
application in the history of the Food & Drug Administration (FDA). In
order to address that controversy, the FDA published an article in the
journal SCIENCE (August 24, 1990).
Data in that paper reveal that the average male rat receiving rbGH
developed a spleen 39.6 percent larger than the spleen of the
control animals after just 90 days of treatment. The spleens from
rbGH-treated females increased in size by a factor of 46 percent. These
are not normal reactions and portray animals in distress. These animals
were "under attack" by the genetically engineered hormone. The spleen
is the first line of defense in a mammal's lymphatic system.
Lab animals treated with rbGH developed lymphatic abnormalities.
This same hormone causing changes in lab animals was introduced into
America's food supply in 1994. As Americans continue to ingest
genetically engineered milk and dairy products, lymphatic cancer
rates soar. Americans have become laboratory subjects in genetic
engineering's experiment, and the resulting data indicates
extreme cause for concern.
Robert Cohen
http://www.notmilk.com